B Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
Predicting response in NSCLC to immunotherapy with autoantibody profiling
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
Learning objectives
After attending this webinar, participants will be able to:
- Understand the biological mechanisms of checkpoint blockade immunotherapy in NSCLC, including its impact on T cell and B cell responses.
- Recognize the incidence, burden and underlying causes of irAEs associated with checkpoint blockade therapy.
- Explore how autoantibody biomarkers were discovered that are linked to treatment response and toxicity.
- Evaluate the potential future applications of B cell biology and autoantibody profiling in advancing personalized immunotherapy and optimizing patient selection for checkpoint blockade treatments.
Gary Middleton, MD, PhD
Professor of Medical Oncology
University of Birmingham
Akshay Patel, PhD
Specialist Registrar in Thoracic Surgery; Clinical Lecturer
Institute of Immunology and Immunotherapy
University of Birmingham
B Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
A presentation by Gary Middleton and Akshay Patel
More webinars
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.